Biogen Inc. (BIIB)
BIIB Stock: Is Biogen Still A Buy After The 14% Spike?
Biogen (BIIB) shares recorded their fifth consecutive day of increases, accumulating a total return of 14% during this span. The company's market value has increased by approximately $3.3 billion over the past 5 days, bringing its current market capitalization to around $23 billion.
Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Biogen Inc. (NASDAQ:BIIB ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDT Company Participants Priya Singhal - Executive VP & Head of Development Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More
Companies on the move in today's trading.
Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Alisha A. Alaimo - President & Head of North America Christopher A.
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $5.47 per share, beating the Zacks Consensus Estimate of $3.93 per share. This compares to earnings of $5.28 per share a year ago.
Biogen raises annual profit forecast on strong demand for rare disease drugs
Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its older multiple sclerosis drugs.
Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.
